AllRock Bio has dosed the first patients in the Phase IIa ROCSTAR clinical trial investigating ROC-101, an oral ...
In patients with post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction, ...
This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ETSAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, ...
Please provide your email address to receive an email when new articles are posted on . Hospitalizations for pulmonary hypertension have increased from 1980 to 2002, resulting in 200,000 ...
Panelists discuss how the future of PAH treatment looks promising with potential for disease remission through reverse remodeling agents, emphasizing the need for continued research focus on patients ...
THE pulmonary circulation is of paramount importance in failure of the heart. The presence of dyspnea, orthopnea and hemoptysis and a diminution in vital capacity imply a profound change in the blood ...
This content was provided by George Washington University Hospital. Mardi Gomberg-Maitland, MD, MSc, is a fellowship-trained cardiologist and professor of medicine at GW Medicine, who also serves as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results